Summary: The present study was undertaken to identify genetic polymorphisms of multidrug resistanceassociated protein 3 (MRP3, gene name ABCC3), an ATP-binding cassette transporter that mediates the transport of substrates across the basolateral membrane into the blood, and to investigate their effects on ABCC3 expression and MRP3 function. We identified genetic polymorphisms of ABCC3 and evaluated the effects by (1) a luciferase reporter gene assay, (2) measuring mRNA levels, and (3) a human pharmacogenomics study with 4-methylumbelliferone glucuronide (4-MUG). Overall, 61 genetic variants were identified in three ethnic populations; of these variants 17 were novel (7 were non-synonymous: 61Arg>Cys, 132Gln>Stop, 221Trp>Stop, 270His>Gln, 548Leu>Gln, 600Lys>Arg, and 1324Arg> His). However, these mutations occurred at very low frequencies (max. 4.7%). The observed allele frequencies showed considerable inter-ethnic differences. The reporter gene assay indicated a significant reduction of transcriptional activity with the ¹1767G>A allele compared to the wild-type allele; however, a decreased expression of ABCC3 mRNA was not detected in human liver samples. A human pharmacokinetic study showed that the ABCC3 genotype in the promoter region was not associated with changes in the pharmacokinetics of 4-MUG, a substrate of MRP3. This is the first study to assess the effects of ABCC3 polymorphisms on human pharmacokinetics; however, further investigations are needed to complete the picture.
Introduction
Multidrug resistance-associated protein 3 ¤MRP3, gene ABCC3¥ is an ATP-binding cassette ¤ABC¥ transporter expressed in adrenal gland, liver, small intestine, colon, and gall bladder in humans. 1¥ Typical substrates of MRP3 are glutathione, glucuronide, sulfate conjugates, and bile salts. 2¥ The expression of MRP3 is up-regulated in patients with Dubin-Johnson syndrome in response to elevated bile salt levels and appears to compensate for the impaired function of MRP2 in the liver.
3,4¥
Recent studies suggest that MRP3 has a significant role in the pharmacokinetics ¤PK¥ of some compounds in mice.
MRP3 is highly expressed on the basolateral membrane of enterocytes and hepatocytes, where it transports substrates into the bloodstream. Kitamura et al. revealed that the permeability of the serosal membrane to 4-methylumbelliferone glucuronide ¤4-MUG¥, suggested as a substrate of MRP3 by in vitro experiments, 5¥ was significantly reduced in Abcc3 %/% mice ¤to 33% of that in wild-type mice¥, suggesting that MRP3 plays a major role in the transport of substrates from enterocytes into the portal vein. 6¥ Also in mice, MRP3 was demonstrated to significantly contribute to the hepatic basolateral excretion of 4-MUG. 7¥ Systemic exposure to 4-MUG ¤AUC in plasma¥ after the oral administration of 4-MU in Abcc3 %/% mice was decreased to 25% of that in wild-type mice. 8¥ Similarly, for clinically important drugs such as methotrexate and fexofenadine, significant reduction of the AUC in plasma and basolateral excretion were observed in Abcc3 %/% mice.
9,10¥
mRNA and protein levels of MRP3 in human liver vary extensively among individuals by 86-and 84-fold, respectively. 11¥ These findings imply that variability in the expression and transport activity of MRP3 is responsible for the inter-individual variability in the pharmacokinetics of MRP3 substrates. However, the mechanism responsible for the variability has not yet been elucidated; furthermore, few human studies have tested MRP3 function. One recent clinical study showed that a single nucleotide polymorphism ¤SNP¥ in the promoter region of ABCC3 ¤%211ChT¥ altered the response to anti-tumor drugs. It found that the ¤%211C/T¦T/T¥ group had significantly lower response rates to chemotherapy ¤most patients treated with etoposide and platinum-based drugs¥ than the %211C/C group. 12¥ Although the effect of the %211ChT genotype on the pharmacokinetics of MRP3 substrates is not clear, these findings suggest some clinical implications of MRP3 function.
In this study, to assess the mechanism responsible for the variability in MRP3 expression and the effect of the %211ChT variant on MRP3 function, we first analyzed genetic variations of the ABCC3 gene in three ethnic groups ¤Japanese, Caucasians, and African-Americans¥. We then assessed their functional impact by ¤i¥ luciferase reporter gene assay, ¤ii¥ quantification of mRNA expression in human liver samples, and ¤iii¥ a human pharmacogenomics ¤PGx¥ study using 4-MUG, one of the substrates of MRP3, conducted in 50 healthy volunteers.
Materials and Methods
Blood and liver samples: Blood samples were obtained from unrelated Japanese, Caucasian, and AfricanAmerican subjects ¤96 of each; Tennessee Blood Services, Memphis, TN¥. Liver tissue samples from 51 Caucasian donors ¤National Disease Research Interchange, Philadelphia, PA¥ were used for the quantification of ABCC3 mRNA expression. Histological records revealed that these samples were non-cirrhotic, non-tumorous, and showed no signs of local cholestasis.
Genomic DNA isolation and cDNA synthesis: Genomic DNA was isolated from blood samples with the use of the Toyobo blood kit ¤Toyobo, Osaka, Japan¥ on a Toyobo HMX-2000 robot ¤Toyobo¥. Total RNA extraction and reverse-transcription ¤RT¥-polymerase chain reaction ¤PCR¥ procedures for liver samples were previously described. 13¥ Briefly, total RNA extracted with an RNAeasy Kit ¤Qiagen, Hilden, Germany¥ was treated with RNase-free DNase I. The samples were then treated with HaeIII and MboII to digest the potential DNA template, prior to RT. The RNA samples were reverse transcribed into first-strand cDNA with 1 µg of total RNA, 4 µl of 5 ' first strand buffer, 4 µl of 0.1 mM DTT, 1 µl of 500 µg/ml random primer ¤Promega, Madison, WI¥, 4 µl of 10 mM dNTP mixture, and 200 units of SuperScript II RNase H % reverse transcriptase ¤Life Technologies, Rockville, MD¥. The reaction was run at 42ôC for 60 min.
Genotyping and haplotype analysis of ABCC3 in three ethnic populations: Genetic variations of ABCC3 sequences, including all 31 exons, their surrounding introns, and approximately 2000 bp of the 5$-flanking region, were examined using DNA samples from the three ethnic populations. ABCC3-specific primers for PCR were designed on the basis of reference sequences of the ABCC3 gene ¤GenBank accession No. AC004591 and AC005921¥ to avoid the amplification of sequences from homologous genes ¤Table 1¥. The PCR was run for 35®40 cycles of 95ôC for 40 s, 50®65ôC for 45 s, and 72ôC for 1 min. The products were analyzed with the single-strand conformation polymorphism ¤SSCP¥ method for screening of genetic variants followed by sequencing. Sequencing was performed directly or after sub-cloning on an ABI 3100 automatic sequencer ¤Applied Biosystems, Foster City, CA¥ using a Big-Dye Terminator Cycle Sequencing Ready Reaction Kit ¤Applied Biosystems¥. Some variants listed in Supplemental Table S1 were identified by the PCR-restriction fragment length polymorphism ¤RFLP¥ method. The haplotype for approximately 2000 bp of the 5$-flanking region was determined with ARLEQUIN Ver. 3.1 software.
Luciferase reporter gene assay: Six major haplotypes were amplified in length for approximately 2000 bp ¤from %2047 to %11 upstream of the ATG codon¥. For amplification, a KpnI restriction site was attached to the forward primer, whereas the reverse primer was flanked by a SmaI site: 5$-CGGGGTACCCTCAAGCCCAGAGCAA-TCTG-3$ ¤forward¥ and 5$-TCCCCCGGGCGCGGCTG-CAAGGAAGGCGAGC-3$ ¤reverse¥. The PCR product was ligated into the KpnI and SmaI sites of the pGL3-basic vector ¤Promega¥. HepG2 cells were transiently transfected by the LipofectAMINE method and cultured in Dulbeccoös modified Eagleös medium ¤Sigma-Aldrich, St. Louis, MO¥ with 10% fetal bovine serum. Briefly, a mixture of 1.0 µl of LipofectAMINE 2000 reagent ¤Invitrogen, Carlsbad, CA¥ and 1µg of reporter plasmid was transfected into the cells and kept there for 48 h. Then, 0.25 µg of the plasmid pRL-CMV ¤Promega¥ containing Renilla luciferase driven by the CMV ¤cytomegalovirus¥ promoter was co-transfected as a control. Luciferase activity was measured using the Dual Luciferase assay system ¤Promega¥. Promoter activity is given as the mean + S.D. of triplicate determinations.
Quantitative real-time PCR: The mRNA levels were measured by real-time PCR using an ABI PRISM 7000 sequence detection system ¤Applied Biosystems¥. Amplification mixtures contained 10 µl of SYBR Premix Ex Taq ¤Takara, Kyoto, Japan¥, 0.4 µl of Rox reference dye, 1 µl of cDNA synthesis mixture, 4 pmol each of the forward and reverse primers, and distilled water in a total of 20 µl. The following primers were used: for the ABCC3 mRNA, 5$-TGATTCCACTCAACGGAGCT-3$ ¤forward¥ and 5$-TGATGCGCGAGTCCTTCA-3$ ¤reverse¥; and for the glyceraldehyde-3-phosphate dehydrogenase ¤GAPDH¥ mRNA, 5$-ATCAAGAAGGTGGTGAAGCAG-3$ ¤forward¥ and 5$-TCGCTGTTGAAGTCAGAGGAG-3$ ¤reverse¥. The results for the ABCC3 mRNA were normalized to those for the GAPDH mRNA. Triplicate measurements were performed for all samples.
Protocol of the human PGx study: After approval by the Ethics Review Boards of Tottori University and Kyushu Clinical Pharmacology Research Clinic, 50 Japanese volunteers ¤40 men, 10 women; age: 20®41 years; weight: 42.6®83.2 kg¥ participated in this study. All subjects gave written informed consent to participate. Genomic DNA was isolated from peripheral blood and ABCC3 genotypes were determined. Each subject was physically normal and had no antecedent history of significant medical illness, concomitant drug use, or hypersensitivity to any drugs. After an overnight fast, each subject received a single oral dose of 400 mg of 4-MU ¤two 200-mg capsules; Kissei, Nagano, Japan¥ with 150 ml of water. Blood samples were obtained prior to dosing and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12 , and 24 h post dose. The samples were immediately centrifuged at 3,000 rpm for 10 min at 4ôC, and each supernatant was stored at %20ôC until analyzed. Urine samples were collected for 0®4, 4®8, 8® 12, and 12®24 h post dose. Urine volumes were measured and recorded, and 50-ml aliquots were stored at %20ôC until analyzed.
Assay of 4-MUG: Concentrations of 4-MUG in plasma and 4-MU, 4-MUG, and 4-MU sulfate ¤4-MUS¥ in urine were determined by high-performance liquid chromatography ¤HPLC¥ with ultraviolet detection as described by Garrett et al. 14¥ A Hypersil C18 column ¤5 µm particle size, 150 ' 4.6 mm, Phenomenex, Torrance, CA¥ was used with a mobile phase consisting of a 60:40 ¤v/v¥ mixture of 50 mM acetate buffer ¤pH 4.7¥ and a 10 mM tetrabutylammonium phosphate methanol solution delivered at a flow rate of 1 ml/min. The bias ¤accuracy¥ and precision each had a coefficient of variation of :10%.
Pharmacokinetic analysis: A non-compartmental PK analysis was performed using the software WinNonlin Professional 5.0.1 ¤Pharsight, Mountain View, CA¥. The area under the curve up to 24 h post dose ¤AUC 0®24 ¥ of 4-MUG was calculated by the log-linear trapezoidal rule. The maximum plasma concentration ¤C max ¥ was obtained directly from the plasma concentration-time curve. The terminal elimination rate constant ¤K el ¥ was calculated by log-linear regression from the terminal post-distribution phase. The glucuronidation metabolic ratio ¤MR G ¥ was calculated as MR G © Ae 4-MUG /Ae TOT , where Ae 4-MUG is the amount of 4-MUG and Ae TOT is the total amount ¤4-MU ¦ 4-MUG ¦ 4-MUS¥ recovered in urine as unchanged 4-MU up to 24 h post dose.
Statistical analysis: Statistical comparisons of the parameters between two groups were performed with the Mann-Whitney U test. Multiple comparisons were performed with the Dunnett test. P g 0.05 was considered significant.
Results
Genotyping and haplotype analysis of ABCC3 in three ethnic populations: Sixty-one single nucleotide polymorphisms ¤SNPs¥ were detected by PCR-SSCP and RFLP analysis in the three ethnic groups. Fourteen SNPs were located in the 5$-flanking region, 27 in the coding region, and 20 in the introns ¤Table 2¥. Of the 61 SNPs, 17 were novel. Of the 27 coding SNPs, 20 were associated with an amino acid change ¤non-synonymous, including 7 novel ones¥; however, their frequencies were quite low ¤g5%¥. The most frequent non-synonymous variation was 4042ChT ¤1348 ArghCys¥ in the African-American population ¤4.69%¥. On the other hand, some variants in the 5$-flanking region were found at relatively high frequency ¤h10%¥. Table 3 shows the result of the haplotype analysis in the 5$-flanking region estimated with ARLEQUIN software. Haplotype patterns and SNP frequencies of the ABCC3 5$-flanking region showed clear ethnic diversity. Haplotype B was the major type in Japanese ¤71.8%¥ and African-Americans ¤47.4%¥, while haplotype C was the major type in Caucasians ¤32.1%¥. In addition, haplotypes G and J existed only in Japanese, haplotypes L to O existed only in Caucasians, and haplotypes P and Q existed only in African-Americans.
Functional assessment of haplotypes in the 5$-flanking region with the luciferase reporter gene assay: To examine whether the haplotypes identified could affect ABCC3 promoter activity, we performed luciferase reporter gene assays. Reporter gene assays with a series of luciferase reporter gene vectors containing the major six haplotype structures ¤patterns A®F¥ of the ABCC3 5$-flanking region indicated a marked decrease in promoter activity in patterns D ¤%1767GhA¥ and E ¤%1767GhA and %260ThA¥ to approximately 50®60% of that in pattern A ¤reference haplotype¥. No other haplotype patterns showed a significant change in luciferase activity ¤Fig. 1¥.
mRNA levels in human liver samples: Based on the results of the luciferase reporter gene assays, ABCC3 mRNA expression in 51 human liver samples was measured with the real-time PCR method, and mean values compared between samples with ¤n © 5¥ and without ¤n © 46¥ haplotype pattern D or E. However, no significant difference or trend was observed in expression levels between carriers and non-carriers, as shown in Figure 2A . In addition, we tested for %211ChT. As shown in Figure 2B , the SNP %211ChT was associated with significantly reduced expression levels. The mean expression levels in the %211T/T and %211 ¤C/C and C/T¥ groups were 0.86 and 1.18, respectively ¤P © 0.0417¥. None of the other polymorphisms were associated with changes in expression levels.
Pharmacokinetics of 4-MUG in healthy volunteers: All participants completed the study according to the protocol without clinically important adverse events resulting from the administration of 4-MU. The mean Ae TOT Continued on next page: 
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up to 24 h post dose was 362 mg ¤90.5% of a given dose¥. The mean MR G , calculated as Ae 4-MUG /Ae TOT , was 0.98 ¤range; 0.95®0.99¥, and the coefficient of variation ¤CV¥ was quite low ¤0.86%¥. The mean plasma concentration-time curves of 4-MUG in %211T/T subjects ¤n © 40¥ and in C/T subjects ¤n © 10¥ are shown in Figure 3 . There was neither a significant difference nor an obvious trend toward a difference between the two groups in plasma concentration profiles and PK parameters of 4-MUG. PK parameters in relation to %211ChT genotype are summarized in Table 4 . Table 3 ) Luciferase reporter gene vectors containing the major haplotype structures of the ABCC3 5′-flanking region (Pat. A-F) were transfected into HepG2 cells with lipofectamine. Luciferase activity was measured after 48 h using the Dual Luciferase assay system and was corrected to the activity of co-transfected Renilla luciferase to account for differences in transfection efficacy. A promoter-less pGL3-basic vector was transfected as a negative control. Data are shown relative to the value for Pat. A and are presented as the mean + S.D. of triplicate determinations. Statistical comparisons were performed with the Dunnett test (*P g 0.05) against Pat. A as a control. luci represents the luciferase-coding gene. SNP. ABCC3 mRNA levels were determined by the real-time PCR method and were corrected to the level of GAPDH mRNA. Short horizontal lines represent the mean value of each group. Statistical comparisons were performed with the Mann-Whitney U test (*P g 0.05). N.S. means not significant.
Furthermore, no significant difference was observed in any PK parameters with regard to other SNPs or haplotype structures ¤including pattern D or E, data not shown¥.
Discussion
As a result of systematic screening of the ABCC3 gene in three ethnic groups, 61 mutations were identified. Among these, 17 mutations were novel ¤including 7 non-synonymous mutations¥, having not been listed in the NCBI SNP database or in previous reports.
15,16¥ Moreover, although their frequencies are very low, two SNPs, 394ChT ¤exon 4¥ and 662GhA ¤exon 6¥, were nonsense mutations, leading to non-functional proteins. Throughout the study, a total of 27 non-synonymous mutations were observed; however, similar to the 7 SNPs mentioned above, frequencies of all non-synonymous mutations were extremely low, suggesting that the broad inter-individual variability in mRNA and protein levels of MRP3 is difficult to explain in term of these non-synonymous SNPs alone.
15,16¥ Thus, we intended to examine the contribution of the promoter SNPs, with insight into the haplotype concept, to phenotypes in this study. Another novel finding was that frequencies not only of SNPs located in exon and intron regions, but of haplotypes in the promoter region, showed substantial inter-ethnic variability ¤Tables 2 and 3¥.
In the promoter region of ABCC3, some variants were found at relatively high frequencies. Luciferase reporter gene assays with 6 major haplotype constructs showed that the promoter activity was decreased in haplotypes D ¤%1767GhA¥ and E ¤%1767GhA and %260ThA¥ but not in pattern F ¤%1767GhA, %1213ChG and %260ThA¥, compared to the control, pattern A. However, as shown in Figure 2 , %1767GhA was not associated with mRNA expression levels in human liver samples. The reason for this discrepancy is not clear, but one possible explanation is the difference in transcriptional conditions between HepG2 cells and the human liver. To identify potential transcription factor-binding sites within the ABCC3 promoter, we performed an analysis with TFSEARCH version 1.3 ¤http://mbs.cbrc.jp/research/db/TFSEARCH.html¥. The program predicted two binding motifs: GATA-1 and v-Myb ¤their binding sites disappeared in the presence of %1767GhA¥. We compared their expression levels between human liver samples and HepG2 cells, used in the current reporter gene assay, with the reverse transcription ¤RT¥-PCR method. Although, the expression level of GATA-1 was comparable between the liver samples and HepG2 cells, the expression of v-Myb was greater in the HepG2 cells ¤Supplemental Fig. S1¥ . The expression of v-Myb was quite low in human livers. This oncogenic transcription factor was reported to activate the expression of several genes, 17¥ so it is supposed that the difference in expression levels of v-Myb between liver samples and HepG2 cells caused the discrepancy. In addition, the number of subjects carrying haplotypes D or E was quite small ¤N © 5¥, and this might have resulted in missing the potential association.
Lang et al. reported that %211ChT significantly decreased ABCC3 mRNA levels in human liver samples. 15¥ The present study confirmed their finding, though no marked effect was observed in the reporter gene assay. It was reported that the results of reporter gene assays using several cell lines did not correspond to the actual mRNA level of ABCC3 in human tissue. 18¥ Although the reason for this discrepancy is not clear, a specific endogenous transcription factor not expressed in HepG2 might be responsible for the downregulation of ABCC3 expression.
After the oral administration of 400 mg of 4-MU, the average Ae TOT was over 90%, indicating that the 4-MU was well absorbed. Furthermore, the ability to glucuronide 4-MU did not differ among individuals because almost all the According to these reports, we expected that if MRP3 expression is decreased by %211ChT, the AUC would decrease because of the reduction of sinusoidal efflux into the blood stream. In addition, no other SNPs in the promoter region affected the PK profile of 4-MUG significantly. Although these results suggest that the genotype in the promoter region of ABCC3 has no marked effect on the PK profiles of MRP3 substrates, we could not involve subjects with the %211C/C genotype. Moreover, the sample size was relatively small. To make firm conclusions about the effect of ABCC3 genotype on pharmacokinetics, further investigations with a sufficient number of subjects, including %211C/C subjects, are needed. Also, it is necessary to confirm the result with other typical substrates of MRP3.
In addition, it is not certain that 4-MUG is a suitable compound for testing human MRP3 function. Even though previously reported in vitro and in vivo findings suggested that MRP3 has a role in PK of 4-MUG, 5,8¥ it is possible that the function of other transporter¤s¥ has a greater impact on human PK of 4-MUG. Experiments in vitro have revealed that some glucuronide conjugates are substrates of human MRP2 and MRP4.
8¥ Abcc4 %/% mice did not show a significant change in the hepatic basolateral efflux of 4-MUG. 7¥ On the other hand, in Mrp2 k.o. rats ¤Eisai hyper-bilirubinimic rats¥, a significant decrease in the biliary excretion of 4-MUG was observed, 19¥ although this route is not considered the main route in humans based on the amount of 4-MUG recovered from urine ¤>90% of dose¥ in the present study. Taking these results into consideration, it is possible that other transporters expressed at hepatocytes contribute to the PK of 4-MUG. Therefore, to obtain a definitive conclusion as to the effect of these SNPs on MRP3 function, it is necessary to perform additional PK studies using other compounds known to be MRP3 substrates.
In the current study, we evaluated the effect of gene polymorphisms on MRP3 functions; however, the geneexpression study was performed using Caucasian liver samples, while the PK study was conducted on Japanese subjects. Although the frequencies of some mutations were different among different ethnic groups, their effects on phenotypes may be identical. So, we considered that the results of the gene-expression study using Caucasian samples could apply to the pharmacogenomic study in Japanese subjects.
Some studies have reported that the response to chemotherapy is influenced by the ABCC3 %211ChT genotype.
12, 20¥ The expression of MRP3 is markedly upregulated compared to that of other ABC transporters in some tumor tissues or cell lines. 21®23¥ The reason for the tissue-or disease-dependent differences in expression mechanisms has not yet been elucidated, although it cannot be ruled out that %211ChT plays a role in transcriptional regulation only in cancer cells.
In summary, as a result of systematic screening of the ABCC3 gene, some novel mutations including nonsense mutations were identified. Most SNPs and haplotypes in the promoter region showed large inter-ethnic variability. Luciferase reporter gene assays showed that the %1767GhA allele affected transcriptional activities; however, similar results were not obtained in human liver samples. In contrast, %211ChT significantly altered mRNA levels. In the PGx study of 4-MUG, no significant difference was observed in any PK parameters with regard to genotype or haplotype in the ABCC3 promoter region, although we could not evaluate PK in %211C/C subjects. This is the first study to evaluate the effects of polymorphisms in ABCC3 on the pharmacokinetics of drugs in humans. Our findings suggest that genetic variation in the promoter region does not have a marked effect on the pharmacokinetics of MRP3 substrates. However, further studies with a sufficient number of subjects, including %211C/C subjects, and investigations with other typical substrates of MRP3 are needed.
